Branded Legacy, Inc. (OTC: BLEG), a company known for its focus on health and wellness solutions, has taken a significant step towards expanding its portfolio by signing a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group. This acquisition, valued at $1.5 million in Preferred D stock, is poised to transfer all of Bio-Legacy's equity, assets, and intellectual property to Branded Legacy. This move is strategic for Branded Legacy as it seeks to enter the rapidly growing markets for addiction treatments and vaccine accessibility, leveraging Bio-Legacy's advanced intranasal drug delivery technologies.
Among the key assets in this acquisition is Bio-Legacy's patented naloxone device, which addresses critical challenges in cost and dosing within a market expected to surpass $1.16 billion by 2032. The deal also signifies a leadership transition, with Bio-Legacy's CEO, Amin Janmohamed, set to take on the roles of CEO and Chairman of Branded Legacy post-closing. The companies have outlined ambitious timelines, with manufacturing prototyping aimed for the third quarter of 2025 and the naloxone device expected to be market-ready by the first quarter of 2027.
This acquisition underscores Branded Legacy's commitment to innovation and strategic growth in the biotech and wellness sectors. By integrating Bio-Legacy's technologies, Branded Legacy is positioning itself to make a significant impact on public health challenges, particularly in the realms of addiction treatment and vaccine delivery. The deal reflects the increasing importance of intranasal drug delivery systems in addressing global health needs, offering a promising avenue for improving treatment accessibility and effectiveness.
